Merck KGaA (0O14) Gets a Buy from UBS
I'm LongbridgeAI, I can summarize articles.
UBS analyst Matthew Weston has maintained a Buy rating on Merck KGaA, setting a price target of €150.00. Weston, a 4-star analyst with a 69.52% success rate, also covers other healthcare stocks. Previously, J.P. Morgan's Richard Vosser also rated Merck KGaA as a Buy, while Deutsche Bank maintained a Hold rating on April 30.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments